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Mesenchymal stromal cells (MSC) are tested in clinical trials to treat graft versus host disease (GvHD) after stem cell trans-
plantation (SCT). In vitro studies demonstrated MSC’s broad immunosuppressive activity. As infections represent a major risk
after SCT, it is important to understand the role of MSC in this context. We analyzed 24 patients (pts) receiving MSC for GvHD
in our Unit between 2009 and 2011. We recorded viral reactivations as measured in whole blood with polymerase chain reaction
for 100 days following MSC administration. In patients with a documented viral reactivation in the ﬁrst 3 days following MSCs
infusionthefrequencyofvirus-speciﬁcIFNgamma-producingcellswasdeterminedthroughenzyme-linkedimmunospotassay.In
ourcohortofpatientsviralreactivationafterMSCinfusionoccurredin45%ofthecases,whichdidnotsigniﬁcantlydiﬀerfromthe
incidence in a historical cohort of patients aﬀected by steroid resistant GvHD and treated with conventional immunosuppression.
No patient presented severe form of infection. Two cases could be checked for immunological response to viral stimulus and
demonstrated virus speciﬁc T-cytotoxic lymphocyte activity. In our experience MSC infusion did not prove to trigger more
frequent or severer viral reactivations in the post transplantation setting.
1.Introduction
Mesenchymal stromal cells (MSCs) are multipotent cells
endowedwithseveralimmunomodulatoryproperties.Firstly
isolated from human bone marrow and characterized by
their ability to self-renew and diﬀerentiate into mesodermic
tissues, in the last decade their immunological potential has
been widely exploited in the attempt to treat inﬂammatory,
autoimmune, and alloimmune diseases [1]. Many groups
have focused their attention on the use of MSC to manage
graft versus host disease (GvHD) in stem-cell-transplanted
patients after the ﬁrst report of clinical success was docu-
mented by Le Blanc et al. in 2004 [2].
Recent studies in vitro and in mouse models [3–6]h a v e
demonstrated that MSCs exert a pleiotropic immune sup-
pressive action on ongoing immune alloreaction. Previous
considerations by several groups have established that MSCs
inhibit T-cell proliferation in response to alloantigens and
nonspeciﬁc mitogens. This process is thought to be mediated
both by the secretion of soluble factors, such as indoleamine
2,3 dioxygenase, HLA-G, prostaglandin E2, and nitric oxide
and by cell-to-cell contact. MSCs are able to inhibit T- and2 Stem Cells International
B-cell proliferation and to impair NK and dendritic cell
activity [7]. Interestingly, in vitro studies demonstrated that
MSCs strongly suppress alloantigen induced T-cell responses
without interfering with the antiviral T-cell activity [8, 9].
Moreover, it has been demonstrated that the ability of MSC
to inhibit T-cell alloresponse is independent from the major
histocompatibility complex [10].
As viral complications in immunocompromised hosts
aﬀected by resistant GvHD still represent a major clinical
concern [11], we tried to understand if the immunosuppres-
siveactivityexertedbyMSCuponinvivoinfusioncouldhave
some impact on the risk for viral reactivations and on the
correct mounting of antiviral immune responses.
The present report analyzes the risk of viral infection
for cytomegalovirus (CMV), Epstein Barr virus (EBV), and
adenovirus (ADV) in a cohort of patients infused with bone-
marrow-derived third-party MSC, expanded with platelet
lysate (PL) under Good Manufacturing Practices (GMP)
conditions, as previously described in details by our group
[12].
2. Patientsand Methods
All patients received MSC for steroid resistant GvHD at
two partner institutions (Ospedale San Gerardo, Monza and
Ospedali Riuniti, Bergamo) from July 2009 to December
2011 and were monitored twice a week for CMV, EBV, or
ADV reactivation, as measured by Polymerase Chain Reac-
tion (PCR) assay in whole blood. Viral reactivation was
deﬁned as evidence of viral load ≥1000 copies/mL in peri-
pheral blood. Only reactivations occurring for the ﬁrst time
after MSC infusion were documented and patients already
receiving antiviral treatment at the time of MSC infusion
were excluded from the analysis. For the purpose of the
present paper, viral detections occurring between day 0
and day +100 after MSC infusion were recorded. Accord-
ing to local policies patients received or did not therapy
with Ganciclovir or Foscavir, antiCD20moAb, or Cidofovir,
r e s p e c t i v e l yf o rC M V ,E B V ,a n dA D V .
Any patient was analyzed in search for symptoms of viral
overt disease if presenting with fever or organ involvement
associated with viral reactivation.
In order to allow a retrospective comparison, all patients
receiving allogeneic stem cell transplantation between Jan-
uary 2007 and December 2008 were analyzed, and those
who had developed viral reactivations after steroid resistant
GvHD,buthadnotreceivedMSC,wereconsideredascontrol
group.
Type of transplantation, T-cell depletion, conditioning
regimen, and number of immunosuppressive lines adminis-
tered at the time of viral reactivation were recorded, as well
as GvHD grading.
In 2 patients reactivating CMV, the frequency of virus-
speciﬁc cells, secreting IFN-γ in response to a cocktail of
CMV-speciﬁc peptides [13] was measured by ELISPOT assay
(EBioscience, San Diego CA, USA), before and at diﬀerent
time points after MSC infusion.
MSCs were obtained from third-party donors after
expansion with PL, as elsewhere described [12]. Patients
receivedMSCaftergivinginformedconsentandbeingregist-
ered in a phase I, bicentric, prospective trial, which had been
approved by local and national authorities. Each MSC infu-
sion aimed at delivering a median dose of 1 × 106/kg body
weight of the recipient, and a minimum of 2 infusions were
given to each patient.
3. Results
3.1. Clinical Monitoring. From July 2009 till December 2011,
24 patients received MSCs on top of the ongoing immu-
nosuppressive therapy to treat steroid resistant GvHD. Of
these, 11 (45%) developed a viral reactivation for the ﬁrst
time after MSC infusion. Other 2 (8.3%) patients had deve-
loped viral reactivation before MSC infusion and were not
analyzed in detail for the purpose of the present study.
All analyzed patients received an allogeneic transplan-
tation for malignant (10 cases) or nonmalignant disease (1
case). Patient number 4 and 14 received a graft from a mis-
matched donor, whereas all other patients received the graft
from either matched related [2] or unrelated [7] donors.
Among our cohort of patients 9 received a fully myeloabla-
tive conditioning, in 4 cases TBI based and 2 got a reduced
intensity conditioning according to local policies. No one of
the analyzed patients received a T-cell depleted graft, but 9
patients received in vivo T-cell depletion as part of GvHD
prophylactic regimen (Table 1). All the described patients
had suﬀered acute GvHD grade II to IV involving 1 (6
cases) or more organs (5 cases). All patients were receiving
immunosuppressive treatment at the time of viral reactiva-
tion. Seven out of 11 patients developed a reactivation from
a single viral agent (Table 2).
CMV was the most common pathogen occurring in 4
seropositive patients who received seronegative graft, as well
as in 3 patients who showed a more favorable serology pat-
tern (donor and recipient CMV IgG positive). All patients
developing CMV infection were treated with Ganciclovir or
Foscavir according to local guidelines. Two patients (UPN
#14 and 16) received a combined Ganciclovir and Foscavir
treatment because of a CMV-related colitis, documented
through gut biopsies. Both patients had developed gut
GvHD. Another patient (UPN #10) switched to Foscavir
treatment to avoid bone marrow toxicity after prolonged
Ganciclovir exposure.
EBV positivity was detected in 6 patients. Four of them
were treated with anti CD20 monoclonal antibodies, but
noneoftheconsideredpatientsdevelopedsignsorsymptoms
of EBV-related posttransplant lymphoproliferative disorder
(PTLD).
A D Vr e a c t i v a t i o no c c u r r e di n3p a t i e n t sa n dw a sd o c u -
mented in stool as well as in blood, whilst in one case (UPN
#16) gut biopsy also revealed ADV positivity. GvHD had
involved gut in all three patients. All of them successfully
received treatment with Cidofovir.
CMV was the most rapid raising infection in our cohort
with a median time of appearance after the ﬁrst MSC infu-
sion of 2 days (range 1 to 31 days) followed by ADV (median
7 days, range 3 to 40 days) and by EBV (median 21 days,
range 1 to 100). Overall, the viral reactivations occurred atStem Cells International 3
Table 1: Patients characteristics.
UPN Diagnosis Conditioning regimen GvHD prophylaxis GvHD IS treatment at viral
reactivation
1 ALL TBI + VP16 CSA + MTX + ATG Acute skin grade II CSA
4 ALL TBI + VP16 CSA + MTX + ATG Acute skin + liver grade III mPDN, MMF
7 MDS BU + CY + MEL CSA + MTX + ATG Acute gut grade III mPDN, MMF
9 MNGIE BU + FLU CSA + MTX + ATG Acute gut grade III mPDN
10 ALL TBI + VP16 CSA + MTX + ATG Acute skin grade II mPDN, CSA
11 AML BU + CY + MEL CSA + MTX + ATG Acute skin + gut + liver grade IV mPDN, MMF,
ETANERCEPT
13 ALL TREO + FLU CSA + MTX + ATG Acute skin grade II CSA
14 ALL TT + BU + FLU CSA + MMF + EDX Acute gut + liver grade III mPDN, CSA
15 AML TREO + FLU CSA + MTX Acute Skin + gut + liver grade III mPDN, CSA
16 ALL TBI + CY CSA + mPDN + ATG Acute gut + liver grade IV
CSA, mPDN, ECP,
PENTOSTATIN
IMATINIB, CAMPATH
17 AML BU + CY CSA + mPDN Acute gut grade IV mPDN, CSA
IS:immunosuppression,ALL:acutelymphoblasticleukemia,AML:acutemyeloidleukemia,MNGIE:mitocondrialneurogastrointestinalencephalomyopathy,
TBI: total body irradiation, BU: busulfan, CY: cyclophosphamyde, MEL: melphalan, TREO: treosulfan, FLU: ﬂudarabine, TT: Thiotepa, CSA: cyclosporine A,
MTX: methotrexate, ATG: antithymocyte globulin, mPDN: methylprednisolon, MMF: mofetilmycophenolate, ECP: extracorporeal photopheresis. GvHD is
graded according to NIH criteria.
Table 2: Viral reactivations details.
UPN Virus Sample Days from MSC
infusion Treatment Outcome
1 EBV Blood 100 Rituximab Alive, no GvHD
4 CMV
EBV
Blood
Blood
13
40
Ganciclovir
Rituximab Alive, no GvHD
7 ADV Blood + stool 7 Cidofovir Alive, no GvHD
9 CMV Blood 1 Ganciclovir Died on day +456 from SCT from sepsis
10 CMV Blood 2 Ganciclovir then Foscavir Alive, no GvHD
11 ADV Blood + stool 3 Cidofovir Died on day +90 from SCT from GvHD
13 EBV Blood 44 Rituximab Alive, no GvHD
14 EBV
CMV
Blood
Blood + gut biopsy
1
7
Rituximab
Ganciclovir+ Foscavir Died on day +129 from SCT from sepsis
15 CMV
EBV
Blood
Blood
1
1
Ganciclovir
None Died on day +168 from SCT from septic shock
16
EBV
CMV
ADV
Blood
Blood + gut biopsy
Blood + gut biopsy
1
1
40
None
Ganciclovir + Foscavir
Cidofovir
Died on day +225 from SCT from GvHD
17 CMV Blood 31 Ganciclovir Died on day +136 from SCT from disease recurrence
EBV: Epstein Barr Virus, CMV: Cytomegalovirus, ADV: Adenovirus, GvHD: Graft versus Host Disease, and SCT: stem cellstransplantation.
a median time of 17 days after the beginning of steroid the-
rapy in these patients.
All the described patients received multiple MSC infu-
sions (range 2 to 8), and viral reactivation was detected in 3
cases after the ﬁrst infusion and in 8 cases after further infu-
sions. None of the patients in our cohort died for viral-relat-
ed causes. Overall survival in this cohort of patients was
45,5% with a median followup of 20 months after MSC infu-
sion (range 6 to 31 months). Concerning MSC and GvHD
treatment, 2 patients of this cohort presented a complete
responsetotreatment,4apartialresponse,3didnotrespond
to MSC treatment, and in 2 cases response to MSC was not
evaluable because of death before day + 28 after the last
MSC infusion, which represented the evaluation time point
according to the present protocol.
3.2. Immunological Monitoring. Trying to understand if,
upon in vivo infusion, MSC could inﬂuence virus-speciﬁc T-
cell-mediated immune responses, we evaluated by ELISPOT
assays the frequency of virus-speciﬁc T cells circulating in
the peripheral blood (PB) of 2 patients experiencing CMV
reactivation soon after MSC infusion (UPN #9 and 14). Both4 Stem Cells International
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Figure 1: Frequency of CMV-speciﬁc T cells, secreting interferon gamma (IFN-γ) in response to a cocktail of CMV-speciﬁc peptides, as
measured by ELISPOT assay in two patients reactivating CMV after having received mesenchymal stem cells (MSCs) for the treatment
of steroid refractory graft versus host disease. Dotted lines on top of the panels indicate Ganciclovir administration. In the upper panel
overall GvHD grading according to NIH criteria is shown. In the central panel Cytomegalovirus (CMV) reactivation trend as measured in
copies/milliliter of peripheral blood (PB) is shown. In the lower panel the number of CMV-speciﬁc IFN-γ producing cells in relation to
MSC infusions as measured in IFN-γ spots/100.000 peripheral blood-mononucleated cells (PBMC) is shown. Black arrows indicate MSC
infusions.
patients showed an increase of CMV-speciﬁc IFN-γ produc-
ing cells in the PB along with CMV reactivation, despite
the concomitant infusion of multiple MSC doses (Figure 1).
In particular, in UPN #9 CMV-speciﬁc cells increased 18
times at day 44 after HSCT, upon CMV reactivation (16700
CMV DNA copies/mL of PB), compared to day 35 (pre-
infection levels). Virus-speciﬁc cells then started to decrease
along with the resolution of CMV infection and raised again
upon a second episode of CMV reactivation at day 86.
Similarly, in UPN #14, CMV-speciﬁc T cells increased up to
4 times along with CMV reactivation at day 80 after HSCT.
3.3. Comparison with Historical Cohort of Patients. Between
January 2007 and December 2008, 52 patients received allo-
geneic stem cell transplantation at San Gerardo Hospital
( M o n z a ) .1 4o ft h e mr e c e i v e ds t e mc e l lf r o ma nH L Ai d e n -
tical related donor, 4 from a related mismatched donor,
andtheremaining patients fromanHLA-matched-unrelated
donor. Six patients received stem cells from cord blood, 42
from bone marrow, and 4 from peripheral stem cells. Only
one graft was T-cell depleted. GvHD prophylaxis includ-
ed ATG in 35 cases. Among this group of patients 20
developed acute-or chronic-steroid-resistant GvHD of grade
IIorseverer.Allofthemreceivedfurtherlinestreatmentafter
steroid according to GvHD and patient characteristics (2 to
6 lines of treatment). 10 of those patients (50%) presented
withviralreactivationafterGvHDonset.5ofthempresented
with a combined EBV and CMV reactivation, one patient
presented with isolated EBV, and 4 with isolated CMV
reactivation. None of these patients exhibited a PTLD nor
CMV disease. Median time from start of GvHD treatment to
viral reactivation was 13 days (range 2 to 39). Eight of these
10 patients are alive with a median followup of 48 months
from HSCT (range 34 to 62 months), none of those patients
died from viral-related causes.
4. Discussion
MSC proved to be a useful tool in managing GvHD resistant
to conventional treatment. According to diﬀerent published
observations, the response rate varies from 52 to 70% and
diﬀers between adults and children [14, 15].
In spite of the clinical evidence of eﬃcacy, it is still unre-
vealedhow thesecellsareableto tunethe alloreactivityin the
recipient. We recently demonstrated that MSCs, upon infu-
sion, are able to convert an inﬂammatory environment to a
more physiological one, both at the cellular level, promoting
the increase of T-reg cells circulating in the peripheral blood
and at the molecular level, diminishing the concentration of
inﬂammatorycytokines[16].However,concernsarerecently
arising about the possibility that MSCs could, through their
immunosuppressive action, impair anti-viral T-cell respons-
es [17].
The question whether these cells could also inﬂuence
other immunological activities of the eﬀector T cells, namely
antiviral and antibacterial capacity, was ﬁrstly addressed byStem Cells International 5
Karlsson et al. [9]. In a very detailed series of assessments,
they documented in 2 diﬀerent patients, that eﬀector func-
tion of virus-speciﬁc T cells could be retained after MSC
infusions. No other clinical detailed data are available, to our
knowledge, to support this initial observation. Meisel et al.
[18]r e p o r t e din vitro antimicrobial activity of MSC, with-
out further assessment on antiviral properties. The only
phase III randomized study, which was so far conducted on
MSCadministration,alsoreportedageneralnoteonunalter-
ed infection rate between the experimental and the control
group of the cohort [19].
Ar e c e n tr e p o r t[ 17] by Ringd´ en et al. describes a cohort
of 31 patients treated with MSC infusion for aGVHD or
hemorrhagic cystitis describing a high incidence of CMV
reactivationsandmilddisease(31%ofCMV-relateddisease).
This high frequency was expected in patients with steroid-
refractory GVHD, which represents a high-risk group for
developing viral diseases. Accordingly, they reported that
CMV disease occurred in a similar number of patients in the
same cohort before MSC infusion.
In our described population the overall viral reactivation
rate after MSC infusion was 45%, with only 8.3% of CMV-
related disease (i.e., colitis). In our cohort, as well as in the
one reported by Ringd´ en, patients were receiving already at
least one line of immunosuppression at the time of MSC
administration. For this reason it is impossible to restrict the
signiﬁcance of our data to MSC administration. It is any-
how relevant to underline that our viral infectious rate was
similartowhatreportedbyothergroupsinpatientsreceiving
experimental treatments for resistant GvHD other than
MSC [20], and that all patients in our cohort were able to
overcome the viral reactivation with conventional treatment,
without reporting any viral-infection-related death. More-
over, a retrospective comparison with a group of patients
who developed viral reactivation after steroid refractory
GvHD and did not receive MSC treatment also revealed
similar percentage of viral reactivations (50% versus 45% in
the MSC treated group) and similar latency between the start
of the steroid therapy and the viral reactivation.
To support our clinical data, we demonstrated, through
immunological monitoring, how patients exposed to CMV
reactivation after MSC infusions were able to mount a phys-
iological antiviral immune response. It is important to note
that both analyzed patients were at the same time respond-
ing to MSC infusions, as demonstrated by the progressive
attenuation of the GVHD overall clinical score. In particular,
the observation that every episode of viral reactivation is
accompanied by an increase of CMV-speciﬁc T cells and that
this increase, along with the adopted antiviral drug therapy,
results in the clearance of the infection, demonstrates that
MSCs do not interfere with the antiviral response. These
results, in line with data already obtained by other authors,
support the concept that MSCs are able, upon in vivo infu-
sion, to suppress GVHD promoting alloantigen induced
T-cell responses sparing somehow virus-speciﬁc immune
responses [9]. This data holds true in our patients even after
r e p e a t e de x p o s i t i o n st oM S C ,t h u sa l l o w i n gas a f er e p e a t e d
use of these cells.
The present paper conﬁrms safety data on the possible
useofMSCintransplantedpatients.Ourexperiencesuggests
that no augmented risk of viral reactivation or disease is pre-
sent for MSC-infused patients, and that those who develop
viral reactivation do not present more severe course of dis-
ease since the capacity to expand virus-speciﬁc T cells is not
impaired.
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